{"disease":{"id":"malignant-ascites","name":"malignant ascites"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04326946","title":"International Alfapump Cohort Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Sequana Medical N.V.","has_results":false},{"nct_id":"NCT06432296","title":"Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":312,"lead_sponsor_name":"Wuhan YZY Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT06436807","title":"PMCF Study of the CE-marked Drainova® ArgentiC Catheter","phase":"","overall_status":"COMPLETED","enrollment_count":169,"lead_sponsor_name":"ewimed GmbH","has_results":false},{"nct_id":"NCT06266091","title":"Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":115,"lead_sponsor_name":"Wuhan YZY Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT02122185","title":"Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":111,"lead_sponsor_name":"University of Chicago","has_results":true},{"nct_id":"NCT03550560","title":"EUS-Guided Drainage of Refractory Malignant Ascites","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Hospital Universitario Virgen Macarena","has_results":false},{"nct_id":"NCT05461430","title":"Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)","phase":"","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Travera Inc","has_results":false},{"nct_id":"NCT04032600","title":"Malignant Ascites in Ovarian Cancer: Impact of Total Paracentesis on Hemodynamics","phase":"NA","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Charite University, Berlin, Germany","has_results":false},{"nct_id":"NCT06433869","title":"The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05477927","title":"Dual-targeting VEGFR1 and PD-L1 CAR-T for Cancers Patients With Pleural or Peritoneal Metastases","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":58,"lead_sponsor_name":"Sichuan University","has_results":false},{"nct_id":"NCT07397819","title":"Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Dong sheng Zhang","has_results":false},{"nct_id":"NCT05501340","title":"PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Second Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT07023042","title":"Kinesio-Taping vs. Usual Care for Malignant Bowel Obstruction With Ascites","phase":"NA","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT04501744","title":"A Study of M701 (EpCAM and CD3) in Malignant Ascites","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Wuhan YZY Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT07435701","title":"Intraperitoneal SK-NK Cell Injection for Advanced Ovarian Cancer With Massive Ascites","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":29,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT05303844","title":"Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":25,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04771676","title":"Intraperitoneal Injection of Oncolytic Viruses H101 for Patients With Refractory Malignant Ascites","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT03230708","title":"Clinical Study of Autologous Erythrocytes Derived MPs Packaging MTX Peritoneal Perfusion to Treat Malignant Ascites","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":18,"lead_sponsor_name":"Hui ting Xu，MD","has_results":false},{"nct_id":"NCT03200106","title":"Retrospective Study in the Use of the Alfapump and the Treatment of Malignant Ascites","phase":"","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Sequana Medical N.V.","has_results":false},{"nct_id":"NCT04051112","title":"Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"Sichuan Clover Biopharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT06991478","title":"SK-NK Injection in Patients With Advanced Solid Tumors Accompanied by Malignant Ascites","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":10,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT07378436","title":"A Clinical Study of GK02 in Malignant Ascites","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":9,"lead_sponsor_name":"Beijing Geekgene Technology Co., LTD","has_results":false},{"nct_id":"NCT02540356","title":"Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true}],"total":23},"guidelines":[],"source":"Drug Landscape verified database"}